Key result
This review discusses the pharmacological profile and clinical trials of rivaroxaban, an oral factor Xa inhibitor, for the prevention and treatment of venous thromboembolism.
Why the study?
Direct oral anticoagulants are replacing heparins and vitamin K antagonists for venous thromboembolism prevention and treatment, creating a need to review rivaroxaban's pharmacology, clinical trials, and areas of uncertainty.
Does rivaroxaban prevent and treat venous thromboembolism compared to heparins and vitamin K antagonists?
Does rivaroxaban prevent and treat venous thromboembolism compared to heparins and vitamin K antagonists?
This review summarizes the development, pharmacology, and clinical trial evidence for rivaroxaban in the prevention and treatment of venous thromboembolism.
Answers are grounded in this paper and cite their sources.
May support rivaroxaban for VTE; leaves open long-term safety in specific populations.
Until recently, heparins and vitamin K antagonists (VKAs) were the cornerstones for prevention and treatment of venous thromboembolism (VTE). This situation changed with the introduction of the direct oral anticoagulants, which are now replacing low-molecular-weight heparin for thromboprophylaxis after elective hip or knee arthroplasty and VKAs for VTE treatment. Rivaroxaban, an oral factor Xa inhibitor, was the first direct oral anticoagulant licensed for VTE prevention and treatment. This paper provides the rationale for factor Xa as a target for anticoagulants, describes the development of rivaroxaban, reviews its pharmacological profile, discusses the clinical trials with rivaroxaban for VTE prevention and treatment and highlights areas of uncertainty.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2019) conducted a review in Venous Thromboembolism. Rivaroxaban was evaluated. This review discusses the pharmacological profile and clinical trials of rivaroxaban, an oral factor Xa inhibitor, for the prevention and treatment of venous thromboembolism.
Synapse has enriched 10 related papers. Consider them for comparative context: